Article thumbnail

Impaired Cell Surface Expression of HLA-B Antigens on Mesenchymal Stem Cells and Muscle Cell Progenitors

By Adiba Isa, Jan O. Nehlin, Hardee J. Sabir, Tom E. Andersen, Michael Gaster, Moustapha Kassem and Torben Barington


HLA class-I expression is weak in embryonic stem cells but increases rapidly during lineage progression. It is unknown whether all three classical HLA class-I antigens follow the same developmental program. In the present study, we investigated allele-specific expression of HLA-A, -B, and -C at the mRNA and protein levels on human mesenchymal stem cells from bone marrow and adipose tissue as well as striated muscle satellite cells and lymphocytes. Using multicolour flow cytometry, we found high cell surface expression of HLA-A on all stem cells and PBMC examined. Surprisingly, HLA-B was either undetectable or very weakly expressed on all stem cells protecting them from complement-dependent cytotoxicity (CDC) using relevant human anti-B and anti-Cw sera. IFNγ stimulation for 48–72 h was required to induce full HLA–B protein expression. Quantitative real-time RT-PCR showed that IFNγ induced a 9–42 fold increase of all six HLA-A,-B,-C gene transcripts. Interestingly, prior to stimulation, gene transcripts for all but two alleles were present in similar amounts suggesting that post-transcriptional mechanisms regulate the constitutive expression of HLA-A,-B, and -C. Locus-restricted expression of HLA-A, -B and -C challenges our current understanding of the function of these molecules as regulators of CD8+ T-cell and NK-cell function and should lead to further inquiries into their expression on other cell types

Topics: Research Article
Publisher: Public Library of Science
OAI identifier:
Provided by: PubMed Central

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.

Suggested articles


  1. (2001). A cellular model system of differentiated human myotubes.
  2. (2008). A combined genotype of KIR3DL1 high expressing alleles and HLA-B*57 is associated with a reduced risk of HIV infection.
  3. (2001). A new mathematical model for relative quantification in realtime RT-PCR.
  4. (2004). A putative regulatory polymorphism in PD-1 is associated with nephropathy in a population-based cohort of systemic lupus erythematosus patients.
  5. (2008). A reservoir of brown adipocyte progenitors in human skeletal muscle.
  6. (2008). Adipose-derived stem cells: isolation, expansion and differentiation.
  7. (2008). All muscle satellite cells are equal, but are some more equal than others?
  8. (2007). Alternative splicing due to an intronic SNP in HMSD generates a novel minor histocompatibility antigen.
  9. (2008). An HIV-1 clade C DNA prime, NYVAC boost vaccine regimen induces reliable, polyfunctional, and long-lasting T cell responses.
  10. (2002). Characterization of the expression of MHC proteins in human embryonic stem cells.
  11. (1992). Class II MHC antigens in normal human skeletal muscle.
  12. (1990). Differential expression of human leukocyte antigen-A, -B, and -C locus specific genes in trophoblast and embryonic cells.
  13. (2006). Differential IFN-gamma stimulation of HLA-A gene expression through CRM-1-dependent nuclear RNA export.
  14. (1991). Differential regulation of HLA-A3 and HLA-B7 MHC class I genes by IFN is due to two nucleotide differences in their IFN response sequences.
  15. (2007). Differentiating human embryonic stem cells express a unique housekeeping gene signature.
  16. (1981). Distribution of HLA class 1 antigens in normal human tissue and in mammary cancer.
  17. (1986). Gamma interferon and 5-azacytidine cause transcriptional elevation of class I major histocompatibility complex gene expression in K562 leukemia cells in the absence of differentiation.
  18. (2004). High frequency of allele-specific down-regulation of HLA class I expression in lung cancer cell lines.
  19. (2010). HIV protective KIR3DL1 and HLA-B genotypes influence NK cell function following stimulation with HLA-devoid cells.
  20. (2003). HLA expression and immunologic properties of differentiated and undifferentiated mesenchymal stem cells.
  21. (2009). Human leucocyte antigen (HLA) expression of primary trophoblast cells and placental cell lines, determined using single antigen beads to characterize allotype specificities of anti-HLA antibodies.
  22. (2007). Human natural killer cells in health and disease.
  23. (2005). Identification of HLA-A*0111N: a synonymous substitution, introducing an alternative splice site in exon 3, silenced the expression of an HLA-A allele.
  24. (2003). IMGT/ HLA and IMGT/MHC: sequence databases for the study of the major histocompatibility complex.
  25. (2007). Immunization with vaccinia virus induces polyfunctional and phenotypically distinctive CD8(+) T cell responses.
  26. (2007). Immunodominant tuberculosis CD8 antigens preferentially restricted by HLAB.
  27. (2008). Immunomodulatory effect of mesenchymal stromal cells: possible mechanisms.
  28. (2009). In silico analysis of microRNAS targeting the HLAG3 9 untranslated region alleles and haplotypes.
  29. (2008). Krmpotic A
  30. (2003). Locus-specific constitutive and cytokine-induced HLA class I gene expression.
  31. (2002). Loss or downregulation of HLA class I expression at the allelic level in acute leukemia is infrequent but functionally relevant, and can be restored by interferon.
  32. (2008). Mesenchymal stem cells in health and disease. Nat Rev Immunol.
  33. (2009). MHC class I antigen presentation: learning from viral evasion strategies.
  34. (1979). Monoclonal antibodies for analysis of the HLA system.
  35. (2007). Natural killer cells, killer immunoglobulin-like receptors and human leucocyte antigen class I in disease.
  36. (1998). Peijnenburg A
  37. (2009). Phenotypic characterization of distinct human bone marrow-derived MSC subsets.
  38. (2001). Proliferation conditions for human satellite cells. The fractional content of satellite cells.
  39. (2005). Reduced insulin-mediated citrate synthase activity in cultured skeletal muscle cells from patients with type 2 diabetes: evidence for an intrinsic oxidative enzyme defect.
  40. (2006). Rosiglitazone modifies the adipogenic potential of human muscle satellite cells.
  41. (2007). Skewed association of polyfunctional antigen-specific CD8 T cell populations with HLAB genotype.
  42. (2008). Structural basis for NKG2A/ CD94 recognition of HLA-E.
  43. (2002). The diabetic phenotype is conserved in myotubes established from diabetic subjects: evidence for primary defects in glucose transport and glycogen synthase activity.
  44. (1995). The human leukocyte antigen A2 interferon-stimulated response element consensus sequence binds a nuclear factor required for constitutive expression.
  45. (2004). The LILR family: modulators of innate and adaptive immune pathways in health and disease.
  46. (2007). The low rate of HLA class I molecules on the human embryonic stem cell line HS293 is associated with the APM components’ expression level.
  47. (2008). The Yin and Yang of HLA and KIR in human disease.
  48. (1996). Tumor escape from immune recognition: lethal recurrent melanoma in a patient associated with downregulation of the peptide transporter protein TAP-1 and loss of expression of the immunodominant MART-1/Melan-A antigen.
  49. (1996). Tumor escape from immune recognition: loss of HLA-A2 melanoma cell surface expression is associated with a complex rearrangement of the short arm of chromosome 6.
  50. (2005). Tumorigenic heterogeneity in cancer stem cells evolved from long-term cultures of telomerase-immortalized human mesenchymal stem cells.
  51. (2007). Ziegler A